Cafeity Get the app

Side effects

GLP-1 medicines and sleep

Sleep comes up in two very different ways with these medicines. For some people the first weeks bring restless nights — often because of nausea or reflux at bedtime. For others, sleep is part of why they are taking one at all: tirzepatide is approved to treat obstructive sleep apnoea.

By the Cafeity teamUpdated 2 min read

The short answer

Insomnia is uncommon on GLP-1 medicines: the liraglutide 3 mg label reports it in 2.4% of people against 1.7% on placebo.1 More often, sleep is disturbed by night-time nausea, reflux or hunger. Separately, tirzepatide is approved in the US to treat moderate to severe obstructive sleep apnoea in adults with obesity.2 An earlier, smaller evening meal helps many people with night-time reflux; persistent poor sleep is worth raising with a clinician.

What the labels report

Insomnia appears in the liraglutide 3 mg label at 2.4% against 1.7% on placebo.1 It is not among the common reactions in the current semaglutide, tirzepatide or orforglipron weight-management labels. The more common sleep-disturbers are the gastrointestinal reactions: reflux and indigestion are worse lying down, and nausea does not keep office hours.

Obstructive sleep apnoea

Tirzepatide is approved in the US to treat moderate to severe obstructive sleep apnoea in adults with obesity. It was tested in two trials, one in people not using a breathing (PAP) machine and one in people who were; the adverse reactions were similar to those in its weight-management trials.2 Whether it suits you, and whether it changes anything about PAP, is a conversation with your sleep specialist or prescriber.

What tends to help

  • An earlier, smaller evening meal and a few hours before lying down, for reflux and nausea.
  • Going easy on alcohol, which the 2025 joint advisory notes may worsen nausea and reflux.3
  • Enough food earlier in the day, so hunger does not wake you.
  • Logging sleep alongside your doses and symptoms for a few weeks, to see what actually moves it.

When to contact your prescriber

Keeping a record of it

Cafeity can read sleep from Apple Health, so nights sit on the same timeline as doses, meals and symptoms without extra logging.

Cafeity weekly summary: protein 110 g a day, energy 981 kcal a day, water 925 ml a day, weight trend 86.7 kg, one symptom day and two of two days logged.
The week at a glance.
Cafeity "Your week, understood" screen: Ora explains that everything is calculated from your own log, offers questions such as "When are my symptoms worst?", and shows the week's protein, energy, water, weight trend, symptom days and a note that protein was 80 g under target.
Ask about patterns in your own record.

Download Cafeity on the App Store

Common questions

Can GLP-1 medicines cause insomnia?
It is uncommon: 2.4% against 1.7% on placebo in the liraglutide 3 mg label, and not among the common reactions on the other weight-management labels.1
Is a GLP-1 approved for sleep apnoea?
Tirzepatide is approved in the US for moderate to severe obstructive sleep apnoea in adults with obesity.2

Sources

  1. Liraglutide 3 mg injection for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 15 June 2026
  2. Tirzepatide injection for weight management and obstructive sleep apnoea — US prescribing information DailyMed, US National Library of Medicine, version published 2 September 2026
  3. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society Mozaffarian D et al. 2025 (published in four journals)

Written by the Cafeity team from the sources listed here. Figures from prescribing information are quoted as the label states them; trial results are averages from those trials, not predictions for any one person. This page has not yet been reviewed by a clinician — see the editorial policy for how pages are researched and corrected.